China is unlikely to launch major fiscal stimulus in H2 2026 as GDP growth stays on track. This market-entry briefing explains why stable macro policy — not stimulus-driven spikes — creates better conditions for foreign companies entering China.
Xiaomi unveiled its first extended-range EV, the SkyNomad, on July 30, 2026, entering a hybrid segment whose sales are weakening and inventories rising. This guide explains what the market shift means for foreign auto suppliers, parts makers, and investors in China's automotive ecosystem.
Hong Kong Exchanges and Clearing will launch China Treasury Bond Futures on August 4, 2026 — the first exchange-traded CGB derivatives available to foreign investors outside the mainland. Here are the 3 steps to access China's US$19.9 trillion bond market.
Hong Kong's Chapter 18C specialist tech regime and Zhongji Innolight's $7B IPO signal a new era for foreign innovative firms. This guide maps three listing pathways — 18C, 18A, and WVR — and the practical steps foreign AI, biotech, and clean energy companies need to take in 2026-2027.
ByteDance split Feishu between Doubao AI and Volcano Engine on July 30. This guide explains service continuity risks, new AI capabilities, and data residency options for foreign companies using Chinese enterprise AI tools.
China's retail sales contracted for the first time since 2022 while industrial output beats estimates. A sector-by-sector map of winners and losers for foreign investors in mid-2026.
After Beijing issued a food safety 'accountability interview' to Walmart's Sam's Club, here is what the process involves and how foreign retailers can stay compliant.
China added 47 new unicorns in H1 2026. ByteDance is now the world's third-most-valuable private company behind OpenAI and Anthropic, while DeepSeek enters the global top 15.
Beijing blacklisted 5 US rare earth companies and published new overseas investment regulations effective July 1. Here is what foreign investors need to know this week.
Beijing's 15-point action plan targets the FDI slide with expanded market access, streamlined operations, and regional pilot alignment. Here's what foreign businesses should do now.
China registered a record 5,215 clinical drug trials in 2025, up 23% from 2024. This market intelligence briefing covers opportunities, risks, and entry points for foreign pharma and biotech investors.